Spyre Therapeutics, Inc.

SYRE Healthcare Biotechnology

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.

EPS
−624.8%
Free cash flow
−108.8%

Quarter to September 2026, against a year earlier

104.18 7.59 +7.86%
Market cap
$9.2B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
3/9
Altman Z
−3.82
Beneish M
n/a
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
27.40 18.53 8.97 13.25
Net Debt/EBITDA
10.14 27.51 16.25 13.23
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.88) (0.82) (0.73) (0.70)
Book value per Share
11.89 13.00 8.54 11.17
Free Cash Flow
(77.49) (69.88) (57.37) (44.58)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026